Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa

Background. Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson’s disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients. Methods. Data were collected from several p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Parkinson's disease Jg. 2020; H. 2020; S. 1 - 11
Hauptverfasser:	Antonini, Angelo, Benesh, Janet, Kukreja, Pavnit, Ijacu, Horia, Bergmann, Lars, Boyd, James T., Poewe, Werner, Zadikoff, Cindy, Robieson, Weining Z.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cairo, Egypt Hindawi Publishing Corporation 2020 Hindawi John Wiley & Sons, Inc Wiley
Schlagworte:	Carbidopa Clinical trials Complications and side effects Datasets Demography Dopa Dopamine Dosage Double-blind studies Drug dosages Dyskinesia Intestine Levodopa Medical research Medicine, Experimental Movement disorders Neurodegenerative diseases Parkinson's disease Patients Pharmaceutical industry Polyneuropathy Quality of life Safety Safety and security measures Studies United States United States > US
ISSN:	2090-8083, 2042-0080
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!